相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST).
I. Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2012)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3
Yasuo Kodera et al.
BREAST CANCER RESEARCH (2011)
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
R. Goodwin et al.
ANNALS OF ONCOLOGY (2010)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Sunitinib for metastatic renal cell carcinoma
Deborah Mukherji et al.
FUTURE ONCOLOGY (2010)
Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
Mariette H. W. Kappers et al.
HYPERTENSION (2010)
Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
Suzanne E. Dahlberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vascular endothelial growth factor pathway
Michael L. Maitland et al.
PHARMACOGENETICS AND GENOMICS (2010)
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
M. Scartozzi et al.
ANNALS OF ONCOLOGY (2009)
Hypertension as a surrogate marker for the activity of anti-VEGF agents
O. Mir et al.
ANNALS OF ONCOLOGY (2009)
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
G. Di Lorenzo et al.
ANNALS OF ONCOLOGY (2009)
Hypertension and proteinuria: a class-effect of antiangiogenic therapies
Vincent Launay-Vacher et al.
ANTI-CANCER DRUGS (2009)
Rapid Development of Hypertension by Sorafenib: Toxicity or Target?
Benjamin D. Humphreys et al.
CLINICAL CANCER RESEARCH (2009)
Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure
Samuel E. DePrimo et al.
CLINICAL CANCER RESEARCH (2009)
Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular pathobiology of gastrointestinal stromal sarcomas
Christopher L. Corless et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor
Neeltje Steeghs et al.
CLINICAL CANCER RESEARCH (2008)
Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST
P. Reichardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Hypertension and targeted therapy Part 2: Small molecule inhibitors of VEGF
Simon Chowdhury et al.
TARGETED ONCOLOGY (2006)
Vascular endothelial growth factor-induced nitric oxide- and PG12-dependent relaxation in human internal mammary arteries - A comparative study with KDR and Flt-1 selective mutants
W Wei et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
AV Chobanian et al.
HYPERTENSION (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
